Brief: Panbela Receives Positive EMA Opinion On Orphan Designation For Ivospemin (SBP-101)
14/12/2022 14:34
Dec 14 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA RECEIVES POSITIVE EMA OPINION ON ORPHAN
DESIGNATION FOR
IVOSPEMIN (SBP-101) IN COMBINATION WITH GEMCITABINE AND
NAB-PACLITAXEL IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL
ADENOCARCINOMA
Source text for Eikon: ID:nGNX6sDMND
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants